Sysmex Corporation (JP:6869)
:6869
Want to see JP:6869 full AI Analyst Report?
6869 Stock Chart & Stats
¥1437.00
¥11.50(0.40%)
At close: 4:00 PM EST
¥1437.00
¥11.50(0.40%)
Day’s Range― - ―
52-Week Range¥1,268.00 - ¥2,710.50
Previous CloseN/A
Volume1.43M
Average Volume (3M)2.38M
Market Cap
¥830.33B
Enterprise Value¥854.63B
Total Cash (Recent Filing)¥75.76B
Total Debt (Recent Filing)¥71.03B
Price to Earnings (P/E)16.4
Beta0.30
Next Earnings
May 14, 2026EPS Estimate
5.93Next Dividend Ex-DateN/A
Dividend Yield1.88%
Share Statistics
EPS (TTM)23.55
Shares Outstanding629,480,100
10 Day Avg. Volume2,693,210
30 Day Avg. Volume2,377,620
Financial Highlights & Ratios
PEG Ratio3.84
Price to Book (P/B)3.81
Price to Sales (P/S)3.48
P/FCF Ratio29.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,750.00Price Target Upside21.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)74.53
Revenue Forecast (FY)¥534.01B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained, multi-year revenue growth reflects durable demand for Sysmex instruments and the expanding installed base. A larger installed base supports recurring reagent and service sales, producing predictable, scalable revenue that underpins medium-term investment and cash generation.
High MarginsRobust gross and operating margins point to product differentiation and pricing power in hematology and related diagnostics. Strong margins fund R&D, service networks, and software, reinforcing competitive advantages and long-term profitability across cycles.
Conservative Balance SheetLow leverage and sizable equity provide financial flexibility for capex, selective M&A, and R&D spend. A conservative balance sheet lowers refinancing risk, enabling sustained investment in installed base expansion and global service capabilities over the medium term.
Bears Say
Weak Cash ConversionFree cash flow converts unevenly versus earnings, leaving only ~56% of net income as FCF. Variable working capital and investment needs can materially swing cash, limiting flexibility for buybacks, dividends or unexpected capex and constraining short-to-medium term liquidity uses.
Net Margin CompressionRecent net margin erosion suggests rising costs, adverse mix, or FX pressure. If persistent, margin compression reduces internal funding for R&D and service expansion, weakens returns on invested capital, and could slow the pace of durable installed-base monetization.
Declining EPSMaterial negative EPS growth despite revenue gains indicates profit conversion challenges or one-off impacts. Continued EPS decline can erode retained earnings, limit reinvestment capacity, and signal operational headwinds that may impair long-term return generation.
Sysmex News
6869 FAQ
What was Sysmex Corporation’s price range in the past 12 months?
Sysmex Corporation lowest stock price was ¥1268.00 and its highest was ¥2710.50 in the past 12 months.
What is Sysmex Corporation’s market cap?
Sysmex Corporation’s market cap is ¥830.33B.
When is Sysmex Corporation’s upcoming earnings report date?
Sysmex Corporation’s upcoming earnings report date is May 14, 2026 which is in 11 days.
How were Sysmex Corporation’s earnings last quarter?
Sysmex Corporation released its earnings results on Feb 12, 2026. The company reported ¥23.55 earnings per share for the quarter, beating the consensus estimate of ¥21.842 by ¥1.708.
Is Sysmex Corporation overvalued?
According to Wall Street analysts Sysmex Corporation’s price is currently Undervalued.
Does Sysmex Corporation pay dividends?
Sysmex Corporation pays a Notavailable dividend of ¥19 which represents an annual dividend yield of 1.88%. See more information on Sysmex Corporation dividends here
What is Sysmex Corporation’s EPS estimate?
Sysmex Corporation’s EPS estimate is 5.93.
How many shares outstanding does Sysmex Corporation have?
Sysmex Corporation has 629,480,100 shares outstanding.
What happened to Sysmex Corporation’s price movement after its last earnings report?
Sysmex Corporation reported an EPS of ¥23.55 in its last earnings report, beating expectations of ¥21.842. Following the earnings report the stock price went up 3.428%.
Which hedge fund is a major shareholder of Sysmex Corporation?
Currently, no hedge funds are holding shares in JP:6869
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sysmex Corporation
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
6869 Stock 12 Month Forecast
Average Price Target
¥1,750.00
▲(21.78% Upside)
Technical Analysis
Options Prices
Currently, No data available
---